Modified bloodroot compound shows promise against multidrug-resistant tuberculosis

FHS
October 8, 2024
11:50 pm

A modified compound taken from bloodroot, a wildflower native to North America, effectively fights multidrug-resistant tuberculosis (TB) bacteria in the test tube, according to a new study.

Turn Bio and HanAll to develop therapies for age-related conditions

The companies will jointly develop therapies for age-related eye and ear ailments. Credit: Yurii_Yarema / Shutterstock.com. Turn Biotechnologies (Turn Bio) has entered an exclusive worldwide

May 29, 2024

SNAP emergency allotments: Reducing food insecurity in children

Study found that emergency SNAP allotments were associated with a decreased risk of food hardship in households with children, particularly among White and Hispanic families,

August 25, 2024

Study shows CAR T-cell therapy’s risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.